POLARIS 2022-001: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
Clinical Trial Grant
Awarded By
Polaris Pharmaceuticals, Inc.
Start Date
July 10, 2024
End Date
April 30, 2029
Awarded By
Polaris Pharmaceuticals, Inc.
Start Date
July 10, 2024
End Date
April 30, 2029